Evaluate released its 2026 Orphan Drugs Report projecting global orphan drug sales will exceed $400 billion annually by 2032, up from 15% of prescription drug sales in 2022 to over 21% of the market in 2032. The analysis names established franchises—J&J’s Darzalex and Vertex’s Alyftrek/Trikafta among leaders—forecasting ten therapies to exceed $6 billion in annual sales. Evaluate cautions that the growth path depends on regulatory decisions, pricing pressures and evolving policy such as IRA exceptions and voucher reauthorizations. The report will inform investor allocations and strategic planning as companies weigh orphan programs, platform investments and commercialization strategies in a crowded specialty market.